1. Home
  2. ELDN

ELDN

Eledon Pharmaceuticals Inc.

Logo Eledon Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 12:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Founded: 2004 Country:
United States
United States
Employees: N/A City: IRVINE
Market Cap: 46.2M IPO Year: N/A
Target Price: $10.67 AVG Volume (30 days): 84.6K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.64 EPS Growth: N/A
52 Week Low/High: $1.07 - $2.95 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: